Philippe Pouletty

Biography

 Dr Philippe Pouletty (MD) is co-founder and general partner of Truffle Capital. He is a renowned Biotech and Medtech industry veteran with dual experience in Silicon Valley and in France. He is founder and chairman of Deinove (ALDEI), co-founder and board member of Carmat (ALCAR), former chairman and board member of Neovacs (ALNEV), chairman of BMD and Splicos, co-founder and board member of Pharnext, Plasmaprime, Vexim, Wittycell, and board member of Immune Targeting Systems, Myopowers, Symetis, and Theraclion, all Truffle Capital portfolio companies. He is also an independent board member of Innate Pharma (Euronext). He founded SangStat (organ transplantation therapeutics) in 1988, did an IPO on NASDAQ in 1993 and sold it to Genzyme for €600m in 2002. He also founded ConjuChem in 1993 and did an IPO on the Toronto Stock Exchange in 2000. He is former chairman (2001-2009) and honorary chairman of France Biotech, the French biotech industry association and former vice chairman of EuropaBio, the European Association for Bioindustries. He is the inventor of 29 patents including the second highest revenue generating life science patent for Stanford University. He has an MD from the University of Paris VI, MS degrees in immunology and virology from Pasteur Institute, was a post-doctoral research fellow at Stanford University and became a laureate of the American Liver Foundation in 1999. He has been awarded the Chevalier de la Légion d’Honneur.

Research Interest

 Pharmaceutical Sciences